A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis

Trial Profile

A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs MEDI 4920 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms MEDI4920 in RA
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Oct 2017 Planned number of patients changed from 40 to 54.
    • 19 Oct 2017 Planned End Date changed from 6 Sep 2017 to 31 Jul 2018.
    • 10 Jul 2017 Planned End Date changed from 1 Aug 2017 to 6 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top